Novo Nordisk’s Share Slump Piles Turnaround Pressure on New CEO

Novo Nordisk A/S began 2025 as Europe’s most valuable listed firm, but obesity drug competition and profit downgrades have left the stock facing its worst year on record — putting...

By Lisa Pham · Bloomberg Markets

Novo Nordisk A/S began 2025 as Europe’s most valuable listed firm, but obesity drug competition and profit downgrades have left the stock facing its worst year on record — putting pressure on its new leader to engineer a turnaround.